close
Add to watchlist
Corcept Therapeutics Inc (CORT) Healthcare, Biotechnology & Drugs
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the development of drugs for the treatment of severe metabolic and psychiatric disorders. The company focuses on the development of drugs for disorders that are associated with irregular levels of the steroid hormone called cortisol. Its lead product is CORLUX, a glucocorticoid receptor II (GR-II) antagonist, which is in Phase III clinical trials for the treatment of Cushing's Syndrome and for psychotic depression. The company is also developing next-generation selective GR-II antagonists for other major metabolic and psychiatric disorders. It has exclusive patent license from Stanford University for the use of GR-II antagonists, as well as has agreements with ICON Clinical Research, LP; and MedAvante, Inc. The company was founded in 1998 and is headquartered in Menlo Park, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.11 |
| Volume | 225064 |
| Volume Avg | 693975 |
| 52 Week High | 5.07 |
| 52 Week Low | 2.50 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.39 |
| EPS change Q/Q | -10% |
| EPS change Q/Q Yr ago | -10% |
| EPS change Q/Q next Q est | -10% |
| EPS change Y/Y | 0% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.10 |
| EPS next Y est | -0.10 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |